Profile data is unavailable for this security.
About the company
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
- Revenue in USD (TTM)1.80m
- Net income in USD-11.54m
- Incorporated2007
- Employees23.00
- LocationAddex Therapeutics LtdChemin des Mines, 9PLAN-LES-OUATES 1202SwitzerlandCHE
- Phone+41 228841555
- Fax+41 228841556
- Websitehttps://www.addextherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cumberland Pharmaceuticals, Inc. | 39.55m | -6.28m | 22.82m | 91.00 | -- | 0.768 | -- | 0.5771 | -0.4448 | -0.4448 | 2.75 | 2.10 | 0.4528 | 0.8383 | 3.45 | 434,643.10 | -7.25 | -7.03 | -10.66 | -9.52 | 84.66 | 79.95 | -16.01 | -17.64 | 1.11 | -25.08 | 0.3041 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
Bioxytran Inc | 0.00 | -4.30m | 22.90m | 2.00 | -- | -- | -- | -- | -0.0297 | -0.0297 | 0.00 | -0.0017 | 0.00 | -- | -- | -- | -2,431.80 | -1,420.53 | -- | -- | -- | -- | -- | -- | -- | -7.69 | -- | -- | -- | -- | -73.71 | -- | -- | -- |
Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 23.02m | 20.00 | -- | -- | -- | 1,770.93 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
Neurosense Therapeutics Ltd | 0.00 | -11.28m | 23.23m | 16.00 | -- | -- | -- | -- | -0.7625 | -0.7625 | 0.00 | -0.1219 | 0.00 | -- | -- | 0.00 | -207.24 | -- | -395.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.59 | -- | -- | -- |
Lisata Therapeutics Inc | 0.00 | -20.84m | 23.51m | 25.00 | -- | 0.479 | -- | -- | -2.58 | -2.58 | 0.00 | 5.91 | 0.00 | -- | -- | 0.00 | -32.63 | -45.97 | -36.16 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
Lipocine Inc | -2.85m | -16.35m | 23.60m | 17.00 | -- | 1.16 | -- | -- | -3.11 | -3.11 | -0.5417 | 3.83 | -0.0942 | -- | -- | -167,695.30 | -54.02 | -39.32 | -58.16 | -45.87 | -- | -- | -- | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
Unity Biotechnology Inc | 0.00 | -39.86m | 24.68m | 19.00 | -- | 0.8689 | -- | -- | -2.75 | -2.75 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -41.95 | -47.21 | -49.03 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
Addex Therapeutics Ltd - ADR | 1.80m | -11.54m | 24.78m | 23.00 | -- | 12.96 | -- | 13.77 | -209.09 | -209.09 | 5.07 | 1.20 | 0.2549 | -- | 14.82 | 78,273.23 | -163.36 | -- | -312.84 | -- | -- | -- | -640.91 | -- | -- | -34.12 | 0.2311 | -- | 13.99 | -- | 49.26 | -- | -- | -- |
Sensei Biotherapeutics Inc | 0.00 | -34.10m | 24.86m | 27.00 | -- | 0.3825 | -- | -- | -1.21 | -1.21 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -35.38 | -47.03 | -38.31 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0247 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
Serina Therapeutics Inc | 142.00k | -14.80m | 25.01m | 4.00 | -- | 1.97 | -- | 176.11 | -13.72 | -13.72 | 0.1316 | 5.07 | 0.0187 | -- | 4.66 | 35,500.00 | -194.80 | -194.46 | -- | -- | 71.83 | 85.80 | -10,430.28 | -2,347.36 | -- | -2.03 | 0.4489 | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
Oncternal Therapeutics Inc | 785.00k | -39.48m | 25.29m | 27.00 | -- | 0.8382 | -- | 32.22 | -13.44 | -13.44 | 0.2672 | 10.19 | 0.0149 | -- | -- | 29,074.07 | -74.93 | -49.40 | -85.36 | -54.51 | -- | -- | -5,029.17 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
Iterum Therapeutics PLC | 0.00 | -38.37m | 25.46m | 14.00 | -- | -- | -- | -- | -2.96 | -2.96 | 0.00 | -0.4743 | 0.00 | -- | -- | 0.00 | -82.44 | -118.12 | -108.84 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 1.51 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
Sol Gel Technologies Ltd | 1.55m | -27.24m | 25.63m | 36.00 | -- | 0.6632 | -- | 16.49 | -1.02 | -1.02 | 0.0574 | 1.39 | 0.0338 | -- | 0.3774 | 43,166.67 | -59.27 | -31.60 | -64.80 | -35.49 | -- | -- | -1,752.77 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
Forte Biosciences Inc | 0.00 | -31.48m | 26.20m | 9.00 | -- | 0.7407 | -- | -- | -1.19 | -1.19 | 0.00 | 0.9719 | 0.00 | -- | -- | 0.00 | -77.74 | -72.06 | -84.92 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
Holder | Shares | % Held |
---|---|---|
J. Stern & Co. LLPas of 31 Dec 2023 | 107.83k | 0.35% |
Armistice Capital LLCas of 31 Dec 2023 | 43.00k | 0.14% |
Jane Street Capital LLCas of 31 Dec 2023 | 0.00 | 0.00% |
Baader Bank AG (Investment Management)as of 31 Dec 2023 | 0.00 | 0.00% |
UBS Securities LLCas of 31 Dec 2023 | 0.00 | 0.00% |